Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis

NCT02590588 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Poor accrual

Conditions

Amyloidosis

Interventions

DRUG: Idelalisib

Sponsor

John Mark Sloan

Collaborators

[object Object]